Search results
Showing 661 to 675 of 1490 results for patients and public
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Extracorporeal shockwave therapy for Achilles tendinopathy (HTG426)
Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]
Awaiting development Reference number: GID-TA11088 Expected publication date: TBC
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids
Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Pharyngeal electrical stimulation for neurogenic dysphagia (HTG709)
Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.
View recommendations for HTG709Show all sections
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
Awaiting development Reference number: GID-TA11705 Expected publication date: TBC
Awaiting development Reference number: GID-TA10833 Expected publication date: TBC
Awaiting development Reference number: GID-TA11691 Expected publication date: TBC
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]
Awaiting development Reference number: GID-TA11362 Expected publication date: TBC
Awaiting development Reference number: GID-TA11059 Expected publication date: TBC
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]
Awaiting development Reference number: GID-TA11305 Expected publication date: TBC